A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 80 600 KRW 3.6% Market Closed
Market Cap: 3.9T KRW

EV/EBIT
Enterprise Value to EBIT

-63.9
Current
-25.1
Median
4.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-63.9
=
Enterprise Value
3.8T KRW
/
EBIT
-59.4B KRW
EBIT Growth EV/EBIT to Growth
KR
A
ABL Bio Inc
KOSDAQ:298380
Average EV/EBIT: 19.7
Negative Multiple: -63.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 973.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.2
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546.4 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.7
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -326.1 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
133.3
2-Years Forward
EV/EBIT
-94.3
3-Years Forward
EV/EBIT
28